Key result
Incidental venous thromboembolism in cancer patients carries similar prognostic implications to symptomatic events, and current evidence supports the use of standard anticoagulation for its management.
Why the study?
Does standard anticoagulation improve outcomes in patients with cancer and incidental venous thromboembolism?
Population
Patients with cancer and incidentally discovered venous thromboembolic events (VTE)
Design
Review
Authors
Loading...
Suggests incidental cancer-associated VTE may merit anticoagulation; leaves open need for randomized confirmation before practice change.
Does standard anticoagulation improve outcomes in patients with cancer and incidental venous thromboembolism?
Incidental VTE in cancer patients should generally be treated with standard anticoagulation, similar to the management of symptomatic events.
O’Connell et al. (2014) conducted a review in Incidental venous thromboembolism (VTE) in cancer patients. Standard anticoagulation was evaluated. Incidental venous thromboembolism in cancer patients carries similar prognostic implications to symptomatic events, and current evidence supports the use of standard anticoagulation for its management.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: